Pfizer Seeks To Nearly Double Shares Of Indian Pfizer Arm
This article was originally published in PharmAsia News
Executive Summary
U.S.-based Pfizer, which already owns 41.2 percent of its Indian subsidiary, Pfizer Ltd., is offering to buy another 33.8 percent to give it 75 percent ownership. The $136 million offer by Pfizer tracks a similar move just weeks earlier by Swiss drug maker Novartis, which sought to increase control of its Indian unit, Novartis India. If Indian regulators approve, Pfizer's offer to shareholders is expected to open in June. (Click here for more
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.